Case Type: Mergers & Acquisitions

Sterling Bancorp, Inc. (Nasdaq: SBT), relating to a proposed merger with EverBank Financial Corp. Under the terms of the agreement, EverBank will acquire all outstanding shares of Sterling Bancorp in an all-cash transaction.

Yotta Acquisition Corporation (NYSE: YOTA), relating to its proposed merger with DRIVEiT Financial Auto Group, Inc. Under the terms of the agreement, DRIVEiT securityholders are expected to own approximately 78.4% of the combined company.

First Majestic Silver Corp. (NYSE: AG), relating to its proposed merger with Gatos Silver, Inc. Under the terms of the agreement, Gatos Silver stock will automatically be converted into the right to receive 2.55 shares of First Majestic common stock.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), relating to a tender offer from H. Lundbeck A/S. Under the terms of the agreement, H. Lundbeck offers to acquire outstanding shares of Longboard common stock for $60.00 per share.

Twin Vee Powercats Co. (Nasdaq: VEEE), relating to its proposed merger with Forza X1, Inc. Under the terms of the agreement, Forza shareholders are expected to receive 0.611666275 shares of Twin Vee per share of Forza they own.

Swiftmerge Acquisition Corp. (Nasdaq: IVCP), relating to its proposed merger with AleAnna Energy, LLC. Under the terms of the agreement, each share of Swiftmerge common stock will automatically be converted into one share of the surviving company.

Atlantic Coastal Acquisition Corp. II (Nasdaq: ACAB), relating to its proposed merger with Abpro Merger Sub Corp. Under the terms of the agreement, each share of Abpro common stock will be converted into the right to receive 2.06 shares of Atlantic Coastal common stock.

Peak Bio, Inc. (OTC: PKBO), relating to its proposed merger with Akari Therapeutics, PLC. Under the terms of the agreement, all Peak Bio common stock will be automatically converted into Akari common stock.

Excientia PLC (Nasdaq: EXAI), relating to its proposed merger with Recursion Pharmaceuticals, Inc. Under the terms of the agreement, each share of Exscientia common stock will be automatically converted into the right to receive 0.7729 shares of Recursion common stock.

Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX), relating to its proposed merger with Exscientia PLC. Under the terms of the agreement, each share of Exscientia common stock will be automatically converted into 0.7729 shares of Recursion common stock.